Changes in fat distribution can affect health, comfort and body image for someone living with HIV. Lipodystrophy can involve fat accumulation, fat loss or both.
Book an appointment2 Million+
Patients served
200,000+
5-star Reviews
12+
Years in operation
300+
Team members and growing
Book Online
Modern. Clean. Extended hours.
Coverage depends on your exact plan, clinician, location and service. Check participation and expected charges with the clinic and your insurer before booking.
174th Street, Bronx, NY
Changes in fat distribution can affect health, comfort and body image for someone living with HIV. Lipodystrophy can involve fat accumulation, fat loss or both.
Confirm whether the chosen location performs the initial assessment, coordinates a specialist or follows an existing treatment plan. Bring prior HIV regimens, metabolic results, fat-change records and cancer/pituitary history. Discuss whether the concern is visceral abdominal fat, fat loss or another cause of swelling so the appointment addresses the actual problem. If Egrifta WR is considered, daily injection teaching, the exact pharmacy product and laboratory monitoring must be arranged. A location listing does not establish medication eligibility or specialist availability. Ask how the responsible HIV clinician remains involved.
Changes in fat distribution can affect health, comfort and body image for someone living with HIV. Lipodystrophy can involve fat accumulation, fat loss or both. Excess visceral fat inside the abdomen differs from fat under the skin and from ordinary weight gain. A useful evaluation identifies the pattern and discusses symptoms, metabolic health and treatment goals. It should not assume every change is caused by the current HIV medication.
HIV, treatment history and other metabolic or hormonal factors can contribute to body changes. Some older antiretroviral exposures are relevant to fat loss, while other causes of weight or abdominal change require assessment. Medication decisions must preserve HIV suppression. Tesamorelin can reduce indicated excess abdominal fat in eligible adults, but it does not treat every type of fat redistribution or replace HIV treatment.
Seek evaluation for a persistent change in abdominal size or loss of fat from the face or limbs, especially if it affects comfort or daily life. New rapid abdominal swelling, severe pain, fluid symptoms or other illness needs prompt assessment for another cause. Age, pregnancy, cancer or pituitary history, diabetes and current medicines influence whether a treatment such as Egrifta WR is suitable.
Discuss where fat has changed, when it began, symptoms and what matters to you. Bring relevant HIV treatment history and prior evaluations, including changes made elsewhere.
The clinician examines the pattern, reviews weight and metabolic measures and decides whether imaging or specialist assessment is needed. Blood glucose, lipid and other tests are chosen for the clinical problem rather than a fixed cosmetic package.
Discuss lifestyle and metabolic care, whether the ART regimen needs specialist review, and medication for the specific indicated pattern. Do not stop an effective antiretroviral regimen to test whether body shape changes.
Agree on the intended benefit, safety tests, who manages HIV care and how the response will be reviewed. If Egrifta WR is chosen, daily injections and formulation-specific teaching are part of the plan.
Bring medication dates, prior photographs or measurements if you want to share them, laboratory results and cancer/endocrine history. Tell the clinician about changes in appetite, strength, fatigue or fluid retention. Ask which findings establish the diagnosis and which uncertainties remain. You do not need to accept a weight-loss plan that fails to address the actual fat-distribution concern.
Preserve HIV suppression while any ART change is considered. Egrifta WR has specific cancer, pituitary and pregnancy contraindications and requires IGF-1 and glucose monitoring. It is not a general obesity treatment, and cardiovascular benefit is not established. Severe pain, rapidly increasing swelling or unexplained systemic symptoms should not wait for a routine body-composition appointment.
Follow-up checks the symptom and fat-distribution goal, metabolic results and any treatment adverse effects. If a medicine is not helping sufficiently, the clinician reviews continued use and alternatives. Changes in body shape can affect mood and confidence; tell the team if distress is interfering with relationships or care so appropriate support can be considered.
Ask whether your visit is an initial assessment, specialist consultation or medication follow-up. Coverage may require documentation of the diagnosed condition and the proposed therapy. Medication, supplies, visits, metabolic testing and specialist referral are separate questions. Confirm the specialist appointment, authorization and intended treatment location for your actual plan.
Nao Medical 174Th Street: 932 E 174th St, Bronx, NY 10460. Call +1-917-310-3371 to confirm the specific service, clinician and appointment before travelling.
Contact the clinic to confirm this service, the clinician and appointment preparation. General clinic hours may differ from service appointment times.
Enter your phone number to begin scheduling your appointment.
You will be redirected to complete the appointment booking. Next: Book Appointment
Nao Medical will never sell your information to a third party.
Choose urgent care for a non-emergency illness or minor injury. For preventive visits and ongoing management, explore primary care at this location.
Visiting later? Review after-hours options and confirm clinic hours before traveling. For a life-threatening emergency, call 911.
The current public clinic record lists 932 E 174th St, Bronx, NY 10460. Confirm the requested service, clinician capability, appointment and any medication delivery at this exact site before traveling. A clinic address does not establish that it administers every treatment.
Ask the selected service for the next available appointment for HIV-associated lipodystrophy assessment. Confirm whether booking or a walk-in visit is appropriate before traveling. Bring the HIV-treatment history and relevant records. Egrifta WR prescribing depends on the clinical assessment and a safe ongoing monitoring plan.
Bring medication dates, prior photographs or measurements if you want to share them, laboratory results and cancer/endocrine history. Tell the clinician about changes in appetite, strength, fatigue or fluid retention. Ask which findings establish the diagnosis and which uncertainties remain. You do not need to accept a weight-loss plan that fails to address the actual fat-distribution concern.
Discuss where fat has changed, when it began, symptoms and what matters to you. Bring relevant HIV treatment history and prior evaluations, including changes made elsewhere.
The clinician examines the pattern, reviews weight and metabolic measures and decides whether imaging or specialist assessment is needed. Blood glucose, lipid and other tests are chosen for the clinical problem rather than a fixed cosmetic package.
Discuss lifestyle and metabolic care, whether the ART regimen needs specialist review, and medication for the specific indicated pattern. Do not stop an effective antiretroviral regimen to test whether body shape changes.
Agree on the intended benefit, safety tests, who manages HIV care and how the response will be reviewed. If Egrifta WR is chosen, daily injections and formulation-specific teaching are part of the plan.
Egrifta WR is tesamorelin for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. It targets a specific clinical problem and is not a general weight-loss medicine. An evaluation distinguishes visceral abdominal fat from ordinary weight gain, fluid retention and other causes of an enlarged abdomen. The benefit being assessed is a change in the indicated fat accumulation, not a promise of weight loss or prevention of heart disease.
The indication is for adults with excess abdominal fat associated with HIV lipodystrophy. Egrifta WR is contraindicated in pregnancy, active malignancy, hypersensitivity and conditions that disrupt the hypothalamic-pituitary axis. A past cancer history needs careful review; it is not interchangeable with active cancer. Diabetes, retinopathy, other endocrine conditions and medicines affect evaluation and monitoring. Safety and effectiveness are not established for a general pediatric weight-management program.
Review the pattern of fat change, symptoms, HIV treatment history and prior evaluations. Agree on a measurable goal and how benefit will be judged, rather than treating a scale target as the indication.
The clinician reviews pituitary problems, cancer history, pregnancy, glucose/diabetes status and IGF-1. Diabetic retinopathy may need particular monitoring.
Egrifta WR is injected under the skin daily. ‘WR’ refers to weekly reconstitution of a vial that supplies daily doses; it is not a once-weekly injection. WR and Egrifta SV have different preparation and dosing instructions and are not interchangeable.
Arrange laboratory monitoring, injection follow-up and assessment of clinical benefit. The clinician may stop treatment if risks outweigh benefit or the response is inadequate.
Follow-up checks IGF-1, glucose and relevant symptoms, along with whether abdominal-fat reduction meets the agreed goal. Monitoring frequency is individualized. Review the daily injection technique and any missed doses, supply problems or side effects. Do not increase doses for a faster response or use research peptides as a substitute. If treatment ends, your clinician discusses what changes may recur and whether another approach is appropriate.
Egrifta WR is injected under the skin daily. ‘WR’ refers to weekly reconstitution of a vial that supplies daily doses. It is not a once-weekly injection. WR and Egrifta SV have different preparation and dosing instructions and are not interchangeable.
Egrifta WR is not interchangeable with Egrifta SV or another tesamorelin formulation. Do not replace its prescribed preparation and dosing with a compounded peptide or assume that sharing an ingredient establishes equivalence, approved use or safety. Ask the HIV clinician and pharmacist to identify the exact product, indication and instructions. Keep HIV treatment separate. Tesamorelin does not replace antiretroviral medicine.
